Mitotanum [INN-Latin] en es it fr

Mitotanum [INN-Latin] Brand names, Mitotanum [INN-Latin] Analogs

Mitotanum [INN-Latin] Brand Names Mixture

  • No information avaliable

Mitotanum [INN-Latin] Chemical_Formula


Mitotanum [INN-Latin] RX_link

Mitotanum [INN-Latin] fda sheet

Mitotanum [INN-Latin] msds (material safety sheet)

Mitotanum_[INN-Latin] MSDS

Mitotanum [INN-Latin] Synthesis Reference

No information avaliable

Mitotanum [INN-Latin] Molecular Weight

320.04 g/mol

Mitotanum [INN-Latin] Melting Point

77 oC

Mitotanum [INN-Latin] H2O Solubility

0.1 mg/L

Mitotanum [INN-Latin] State


Mitotanum [INN-Latin] LogP


Mitotanum [INN-Latin] Dosage Forms


Mitotanum [INN-Latin] Indication

For treatment of inoperable adrenocortical tumours; Cushing's syndrome

Mitotanum [INN-Latin] Pharmacology

Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol.

Mitotanum [INN-Latin] Absorption

About 40% oral Lysodren is absorbed

Mitotanum [INN-Latin] side effects and Toxicity

No information avaliable

Mitotanum [INN-Latin] Patient Information


Follow the links

Mitotanum [INN-Latin] Organisms Affected

Humans and other mammals